Sotalol for ventricular tachyarrhythmias: Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure

James A. Reiffel*, Elizabeth Hahn, Vernon Hartz, Michael J. Reiter

*Corresponding author for this work

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial, d,l-sotalol was associated with a lower arrhythmia recurrence and mortality than class I antiarrhythmic drugs. To further evaluate the relative efficacy of d,l-sotalol compared with class I drugs, and to assess the relative importance of its class II (β-blocking) and class III effects, 6-year arrhythmia recurrence and mortality in patients receiving sotalol were compared with those in patients receiving class I drugs, subdivided according to whether they also received coadministered β blockers. Relative efficacy was also determined far sotalol and for class I drugs as stratified by the presence/absence of prior drug failure. Arrhythmia recurrence was lower for the 84 patients receiving sotalol than for patients given class I agents with (n = 28) (p = 0.008) or without (n = 184) (p = 0.001) a β blocker. Mortality was lower for patients taking sotalol than for those given a class I drug without a β blocker (p = 0.034), but similar (p = 0.835) if a β blocker was also administered. In contrast to class I drugs, which had lower efficacy rates when prior drug trials had failed, sotalol maintained its efficacy despite prior drug failures preceding or during the ESVEM trial. Both class II and III actions in the ESVEM trial were important to the clinical superiority of sotalol in the treatment of ventricular tachyarrhythmias.

Original languageEnglish (US)
Pages (from-to)1048-1053
Number of pages6
JournalAmerican Journal of Cardiology
Volume79
Issue number8
DOIs
StatePublished - Apr 15 1997

Fingerprint

Sotalol
Tachycardia
Pharmaceutical Preparations
Cardiac Arrhythmias
Recurrence
Mortality
Anti-Arrhythmia Agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{dcf017e30d144e3894abe9ecade8d63c,
title = "Sotalol for ventricular tachyarrhythmias: Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure",
abstract = "In the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial, d,l-sotalol was associated with a lower arrhythmia recurrence and mortality than class I antiarrhythmic drugs. To further evaluate the relative efficacy of d,l-sotalol compared with class I drugs, and to assess the relative importance of its class II (β-blocking) and class III effects, 6-year arrhythmia recurrence and mortality in patients receiving sotalol were compared with those in patients receiving class I drugs, subdivided according to whether they also received coadministered β blockers. Relative efficacy was also determined far sotalol and for class I drugs as stratified by the presence/absence of prior drug failure. Arrhythmia recurrence was lower for the 84 patients receiving sotalol than for patients given class I agents with (n = 28) (p = 0.008) or without (n = 184) (p = 0.001) a β blocker. Mortality was lower for patients taking sotalol than for those given a class I drug without a β blocker (p = 0.034), but similar (p = 0.835) if a β blocker was also administered. In contrast to class I drugs, which had lower efficacy rates when prior drug trials had failed, sotalol maintained its efficacy despite prior drug failures preceding or during the ESVEM trial. Both class II and III actions in the ESVEM trial were important to the clinical superiority of sotalol in the treatment of ventricular tachyarrhythmias.",
author = "Reiffel, {James A.} and Elizabeth Hahn and Vernon Hartz and Reiter, {Michael J.}",
year = "1997",
month = "4",
day = "15",
doi = "10.1016/S0002-9149(97)00045-3",
language = "English (US)",
volume = "79",
pages = "1048--1053",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

Sotalol for ventricular tachyarrhythmias : Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. / Reiffel, James A.; Hahn, Elizabeth; Hartz, Vernon; Reiter, Michael J.

In: American Journal of Cardiology, Vol. 79, No. 8, 15.04.1997, p. 1048-1053.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sotalol for ventricular tachyarrhythmias

T2 - Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure

AU - Reiffel, James A.

AU - Hahn, Elizabeth

AU - Hartz, Vernon

AU - Reiter, Michael J.

PY - 1997/4/15

Y1 - 1997/4/15

N2 - In the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial, d,l-sotalol was associated with a lower arrhythmia recurrence and mortality than class I antiarrhythmic drugs. To further evaluate the relative efficacy of d,l-sotalol compared with class I drugs, and to assess the relative importance of its class II (β-blocking) and class III effects, 6-year arrhythmia recurrence and mortality in patients receiving sotalol were compared with those in patients receiving class I drugs, subdivided according to whether they also received coadministered β blockers. Relative efficacy was also determined far sotalol and for class I drugs as stratified by the presence/absence of prior drug failure. Arrhythmia recurrence was lower for the 84 patients receiving sotalol than for patients given class I agents with (n = 28) (p = 0.008) or without (n = 184) (p = 0.001) a β blocker. Mortality was lower for patients taking sotalol than for those given a class I drug without a β blocker (p = 0.034), but similar (p = 0.835) if a β blocker was also administered. In contrast to class I drugs, which had lower efficacy rates when prior drug trials had failed, sotalol maintained its efficacy despite prior drug failures preceding or during the ESVEM trial. Both class II and III actions in the ESVEM trial were important to the clinical superiority of sotalol in the treatment of ventricular tachyarrhythmias.

AB - In the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial, d,l-sotalol was associated with a lower arrhythmia recurrence and mortality than class I antiarrhythmic drugs. To further evaluate the relative efficacy of d,l-sotalol compared with class I drugs, and to assess the relative importance of its class II (β-blocking) and class III effects, 6-year arrhythmia recurrence and mortality in patients receiving sotalol were compared with those in patients receiving class I drugs, subdivided according to whether they also received coadministered β blockers. Relative efficacy was also determined far sotalol and for class I drugs as stratified by the presence/absence of prior drug failure. Arrhythmia recurrence was lower for the 84 patients receiving sotalol than for patients given class I agents with (n = 28) (p = 0.008) or without (n = 184) (p = 0.001) a β blocker. Mortality was lower for patients taking sotalol than for those given a class I drug without a β blocker (p = 0.034), but similar (p = 0.835) if a β blocker was also administered. In contrast to class I drugs, which had lower efficacy rates when prior drug trials had failed, sotalol maintained its efficacy despite prior drug failures preceding or during the ESVEM trial. Both class II and III actions in the ESVEM trial were important to the clinical superiority of sotalol in the treatment of ventricular tachyarrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0030916919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030916919&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(97)00045-3

DO - 10.1016/S0002-9149(97)00045-3

M3 - Article

C2 - 9114762

AN - SCOPUS:0030916919

VL - 79

SP - 1048

EP - 1053

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -